A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCT01235520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

595

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Placebo
DRUG: RO4917838
DRUG: RO4917838

Sponsor

Hoffmann-La Roche